All Photos(1)

Documents

COO/COA

20051

ORBO^™ 609 Amberlite^™ XAD^®-2 (20/50) 400/200 mg

Name: ORBO™ 609 Amberlite™ XAD®-2 (20/50) 400/200 mg
Brand: SUPELCO

W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea

Synonym(s):

ORBO^™ Amberlite^™ XAD-2 Tube

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

UNSPSC Code:

47131900

material

W,W,W separators

Quality Level

100

Agency

NIOSH 2534,2537

product line

Amberlite^™
ORBO^™

composition

Bed A, 400 mg
Bed B, 200 mg

packaging

pkg of 50 ea

manufacturer/tradename

ORBO^™ 609

technique(s)

active air sampling: suitable

O.D. × L

8 mm × 110 mm

matrix

XAD-2

particle size

20-50 mesh

application(s)

air monitoring
environmental
industrial hygiene

Looking for similar products? Visit Product Comparison Guide

Related Categories

Air Monitoring Devices & Tubes

General description

ORBO^™ 609 Amberlite^™ XAD^®-2 (20/50), 400/200 mg sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Amberlite is a trademark of DuPont de Nemours, Inc.

ORBO is a trademark of Sigma-Aldrich Co. LLC

XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of probenecid, verapamil and progesterone on the concentration-dependent and temperature-sensitive human erythrocyte uptake and export of guanosine 3',5' cyclic monophosphate (cGMP).

K Flo et al.

Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)

Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed

Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.

Bjørn T Moe et al.

Anticancer research, 29(4), 1047-1052 (2009-05-06)

Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on

[How hazardous is the use of female steroid hormones?].

A Orbo et al.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)

The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.

Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa).

Anne Ørbo et al.

The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)

Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine

Serum modifies the concentration-dependent effects that sex steroids exert on cgmp and cAMP levels, and the growth of human c4-I cells (carcinoma of the uterine cervix).

A Orbo et al.

International journal of oncology, 5(3), 619-625 (1994-09-01)

About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service